التفاصيل البيبلوغرافية
| العنوان: |
Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors. |
| المؤلفون: |
Aguiar-Bujanda, David, Dueñas-Comino, Arancha, Saura-Grau, Salvador, Ros-Sanjuan, Laura, Blanco-Sanchez, Maria J., Hernandez-Sosa, Maria, Mori-De Santiago, Marta, Galvan-Ruiz, Saray, Lorenzo-Barreto, Jose E., Vargas-Prado, Ana M., Bohn-Sarmiento, Uriel |
| المصدر: |
Oncology Research & Treatment; Nov2018, Vol. 41 Issue 12, p755-761, 7p |
| مصطلحات موضوعية: |
EPIDERMAL growth factor receptors, NON-small-cell lung carcinoma, PROGRESSION-free survival, MULTIVARIATE analysis, METASTASIS |
| مستخلص: |
Background: A high neutrophil to lymphocyte ratio (NLR) has been associated with adverse outcomes in non-small cell lung cancer (NSCLC). However, information on epidermal growth factor receptor (EGFR)-mutant advanced NSCLC is scarce, and most of the studies published have been conducted in Asian populations. We aimed to assess the influence of pretreatment NLR on progression-free survival (PFS) and overall survival (OS) in Western European patients treated with EGFR tyrosine kinase inhibitors (TKIs). Methods: A retrospective evaluation of 41 patients with EGFR-mutant advanced NSCLC treated with EGFR TKIs between June 2010 and May 2016 was carried out. The association between several prognostic factors including pretreatment NLR and survival was analyzed. Results: Median PFS and OS were 10.58 and 20.84 months, respectively. OS for patients with a high NLR was 7.4 months, compared to 24.6 months for patients with a low NLR (p = 0.0122). In multivariate analysis, poor performance status (ECOG PS ≥ 2) and presence of ≥ 3 metastatic locations were identified as significant independent prognostic factors for worse PFS. For OS, unfavorable prognostic factors were a high NLR and central nervous system metastasis at diagnosis. Conclusion: Pretreatment NLR is an independent prognostic factor for OS in Western European patients with EGFR-mutant NSCLC treated with EGFR TKIs. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncology Research & Treatment is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
